Form 4: Director Molly Joseph Receives WST Equity Grant

Director Molly Joseph acquired 791 restricted stock units in West Pharmaceutical Services, Inc. as part of an equity grant.

Summary

• Director Molly Joseph was granted 791 restricted stock units (RSUs) of West Pharmaceutical Services, Inc. (WST) common stock.
• The transaction occurred on May 4, 2026, at a price of $0 per share, representing an equity award.
• Following this transaction, the director's total beneficial ownership increased to 4,398.187 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine director compensation rather than a strategic shift or market-moving financial development.

Positives

• The grant aligns the director's interests with those of shareholders through increased equity ownership.

Negatives

• None identified; this is a standard director compensation event.

Risks

• None identified; this is a standard regulatory disclosure of an equity grant.

Future Outlook

The restricted stock units are scheduled to vest in full on the date of the next annual shareholder meeting.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the pharmaceutical services sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The issuance of restricted stock units to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Vesting of the 791 restricted stock units upon the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Equity Grant